Cannabinoids in Oncology and Immune Response

Lorimier, Louis-Philippe de; Hazzah, Trina; Almeida, Erik Amazonas de; Cital, Stephen

doi:10.1007/978-3-030-68317-7_10

Cited by 3 publications

(3 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the possible use of Cannabis in animals, several areas of interest have been considered, such as pain management (acute and chronic pain) (16), neurological conditions (seizures, neuroinflammation, degenerative diseases, brain tumors) (17), wellbeing (anxiety disorders) (18), gastrointestinal health (appetite modulation, nausea and vomiting, visceral pain/hypersensitivity, esophageal reflux, diarrhea/peristalsis) (19), dermatologic diseases (skin inflammation, wound healings, skin allergies, pruritus) (20), oncology and immune response (21).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge

2023

View full text Add to dashboard Cite

In the last 5 years, interest has grown in using phytocannabinoids, particularly cannabidiol (CBD), in veterinary medicine to treat several pathologies, including pain, epilepsy, anxiety, nausea, anorexia, skin lesions, and even some types of cancer, among others. Indeed, due to a positive perception of CBD use, many pet owners are increasingly requesting this option to relieve their pets, and many veterinarians are exploring this possibility for their patients. Besides the widespread empiric use of CBD in pets, the research is trying to obtain proof of its efficacy and lack of adverse effects and to know its pharmacokinetics to define an appropriate posology. This review summarizes all data published so far about the canine pharmacokinetics, efficacy, and tolerability of CBD and cannabidiolic acid (CBDA). Despite a certain number of available pharmacokinetic studies, the kinetic profile of CBD has yet to be fully known, probably because of the very different experimental conditions. In terms of efficacy, most studies have tested CBD’ ability to relieve osteoarthritic pain. In contrast, few studies have evaluated its role in epilepsy, behavioral disorders, and skin lesions. From obtained results, some evidence exists supporting the beneficial role of CBD. Nevertheless, the limited number of published studies and the occurrence of bias in almost all require caution in interpreting findings. From tolerability studies, CBD’ side effects can be classified as mild or unremarkable. However, studies were prevalently focused on short- to medium-term treatment, while CBD is usually employed for long-term treatment. Further studies are warranted to define better whether CBD could be a valid adjunct in canine treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge

2023

View full text Add to dashboard Cite

show abstract

“…The novelty raised in this study lies in the relationship between cannabinoid-producing agricultural activity and the requirement of the endocannabinoid system of the human brain. Although there are studies on the importance of the endocannabinoid system in the human brain [20][21][22][23][24][25][26][27][28][29][30][31][32][33], the K coefficient has managed to generate a new tool to understand the influence of legality, increase protection and promotion of health, as well as encourage multidisciplinary research that encompasses the agricultural field, health, or neurochemistry.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the human brain has an endocannabinoid system that develops the nervous system and activity in the brain, which is useful for new therapies as it is interrelated with treatment status, disease progression, and severity of symptoms. [20][21][22]. However, what is important about the system is the ability to complement itself with the homeostasis of the brain and its physiology, as well as with regulatory enzymes and peripheral tissues [23][24][25][26][27][28].…”

Section: Introductionmentioning

confidence: 99%

Hemp Genotype Selection Coefficient to Improve Human Welfare Development

Santos¹,

Santos²,

Rodríguez³

2023

Proceedings of the 21th LACCEI International Multi-Conference for Engineering, Education and Technology (LACCEI 2023): “Leaders

View full text Add to dashboard Cite

The new concept of industrial hemp genetic selection examines the relationship levels of the Human Wellbeing Coefficient (K), and the variables grouped in three dimensions of promotion and protection human health with legality framework. The industrial hemp population was 47 hybrids. Eighteen samples were made for each hybrid during six weeks of evaluation. The Hewlett Packard 1100 HPLC equipment was used to analyze the fresh inflorescence samples during the 2019-2020 agricultural season in Montevideo, Uruguay. The hypothesis test, linear regression analysis, ANOVA, Decision Tree, PCA, HCA and Nearest Neighbor Analysis were used as statistics. The coefficient K has a statistically significant positive correlation with the variable Total Cannabidiols -TCBD (CC = ,978; p <.005). It also with the Total Tetrahydrocannabinols -TTHC variable (CC = ,936; p <.005) and with the Full Protection Projection -R1s variable (CC = ,979; p <.005). It is observed that the K coefficient is negatively correlated with the Coefficient of Promotion -R9. When K values increase, the probability of increasing the promotion and protection of human health is higher (R2=0,99; F(4,841) = 30.974.72; Sig = ,000). Hybrids whose K values >4.82 were selected. From the analysis of PCA and HCA, it has been possible to select the six best hybrids and were grouped into two categories. The first group of superior hybrids. This analysis confirmed the potency of the K Coefficient to select hybrids that contain the highest capacity to promote and protect human health.

show abstract

Case report: Cannabinoid therapy for discoid lupus erythematosus in a dog

da Silva,

Christianetti,

Amazonas

et al. 2024

Front. Vet. Sci.

Self Cite

View full text Add to dashboard Cite

Discoid lupus erythematosus (DLE) is a common autoimmune skin disease in dogs. Conventional treatments, such as corticosteroids, can be effective but often have side effects. This case report presents a successful use of cannabinoid therapy (CT) in a dog with DLE resistant to conventional treatment. A 2-year-old mixed-breed dog with a history of DLE presented with worsening lesions despite treatment with corticosteroids and other medications. Liver enzymes levels were elevated, indicating corticosteroid-induced side effects. CT with a CBD-rich full spectrum Cannabis oil was initiated. The dosage was gradually adjusted until the minimum effective dose was found. Within a few weeks of starting CT, the dog showed significant improvement in skin lesions and in liver enzymes levels. After 1 year, the dog remains clinically stable on a low dose of full-spectrum CBD-rich oil. No evidence of DLE recurrence was observed. This case suggests that CT may be a viable alternative or complementary therapy for DLE in dogs, particularly for those experiencing adverse effects from conventional treatments. Further research is warranted to confirm the efficacy and safety of CT for DLE management in dogs.

show abstract

Cannabinoids in Oncology and Immune Response

Cited by 3 publications

References 119 publications

Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge

Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge

Hemp Genotype Selection Coefficient to Improve Human Welfare Development

Case report: Cannabinoid therapy for discoid lupus erythematosus in a dog

Contact Info

Product

Resources

About